Steiner Annabel, Schmidt Stefan Andreas, Fellmann Cara Sophie, Nowak Johannes, Wu Chin-Lee, Feldman Adam Scott, Beer Meinrad, Cheng Leo L
Department of Pathology, Harvard Medical School/Massachusetts General Hospital, Boston, MA 02114, USA.
Department of Diagnostic and Interventional Radiology, University Hospital Ulm, 89081 Ulm, Germany.
Cancers (Basel). 2022 Apr 26;14(9):2162. doi: 10.3390/cancers14092162.
The aim of our study was to assess ex vivo HRMAS (high-resolution magic angle spinning) H NMR spectroscopy as a diagnostic tool for early PCa detection by testing whether metabolomic alterations in prostate biopsy samples can predict future PCa diagnosis. In a primary prospective study (04/2006-10/2018), fresh biopsy samples of 351 prostate biopsy patients were NMR spectroscopically analyzed (Bruker 14.1 Tesla, Billerica, MA, USA) and histopathologically evaluated. Three groups of 16 patients were compared: group 1 and 2 represented patients whose NMR scanned biopsy was histobenign, but patients in group 1 were diagnosed with cancer before the end of the study period, whereas patients in group 2 remained histobenign. Group 3 included cancer patients. Single-metabolite concentrations and metabolomic profiles were not only able to separate histobenign and malignant prostate tissue but also to differentiate between samples of histobenign patients who received a PCa diagnosis in the following years and those who remained histobenign. Our results support the hypothesis that metabolomic alterations significantly precede histologically visible changes, making metabolomic information highly beneficial for early PCa detection. Thanks to its predictive power, metabolomic information can be very valuable for the individualization of PCa active surveillance strategies.
我们研究的目的是通过测试前列腺活检样本中的代谢组学改变是否能够预测未来的前列腺癌诊断，来评估离体高分辨率魔角旋转氢核磁共振波谱（HRMAS H NMR）作为早期前列腺癌检测的诊断工具。在一项前瞻性初步研究（2006年4月 - 2018年10月）中，对351例前列腺活检患者的新鲜活检样本进行了核磁共振波谱分析（美国马萨诸塞州比勒里卡的布鲁克14.1特斯拉仪器）并进行了组织病理学评估。比较了三组各16例患者：第1组和第2组代表核磁共振扫描活检结果为组织学良性的患者，但第1组患者在研究期结束前被诊断出患有癌症，而第2组患者仍为组织学良性。第3组包括癌症患者。单代谢物浓度和代谢组学图谱不仅能够区分组织学良性和恶性前列腺组织，还能够区分在接下来几年中被诊断为前列腺癌的组织学良性患者和仍为组织学良性的患者的样本。我们的结果支持以下假设：代谢组学改变显著先于组织学可见变化，这使得代谢组学信息对早期前列腺癌检测非常有益。由于其预测能力，代谢组学信息对于前列腺癌主动监测策略的个体化可能非常有价值。
